Skip to main content
Erschienen in: Supportive Care in Cancer 7/2005

01.07.2005 | Original Article

Changes in quality of life during palliative chemotherapy for solid cancer

verfasst von: Soo-Mee Bang, Se Hoon Park, Hee Geun Kang, Jung In Jue, In Hee Cho, Young Ho Yun, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2005

Einloggen, um Zugang zu erhalten

Abstract

Background

We conducted this prospective study to assess the changes in quality of life (QOL), anxiety and depression in patients receiving palliative chemotherapy for solid cancers.

Patients and methods

Patients were eligible if they had histologically confirmed metastatic or recurrent cancer and a life expectancy of more than 6 months, and were able to complete the self-administered questionnaires. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) and Hospital Anxiety and Depression Scale (HADS) were used to measure the effects of chemotherapy on the patients’ QOL, anxiety and depression at baseline and three times after every three cycles of chemotherapy.

Results

From July 2001 to October 2003, 146 patients were recruited, and of these 98 completed the questionnaires and 48 were withdrawn from the trial (27 lost to follow-up, 11 withdrew consent, 5 for toxicity, 5 for progression of the cancer). Their median age was 58 years (range 28–78 years) and the male to female ratio was 1.6. Of the 146 patients, 52 had gastric cancer, 39 non-small-cell cancer, 29 colorectal cancer, 11 breast cancer, and 15 had other cancers. Initial QOL scores were closely related to performance status. Compared with baseline, clinically meaningful relief (score decreased by more than 10) of symptoms such as pain and sleep disturbance was observed. There was significant improvement (score increased by more than 10) in the functional scales after the first cycle of chemotherapy, but these effects did not persist throughout the whole course of therapy. The incidences of probable anxiety and depression disorder before chemotherapy were 20% and 29%, respectively. The anxiety scores decreased throughout the period of intervention. Pretreatment anxiety and depression were negatively correlated with baseline QOL scores.

Conclusions

Palliative chemotherapy treatment in patients with solid cancer improved cancer-related symptoms, lessened anxiety and did not disturb the QOL of cancer patients.
Literatur
1.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al (1993) The European Organization for Research and Treatment of Cancer EORTC QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al (1993) The European Organization for Research and Treatment of Cancer EORTC QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRefPubMed
2.
Zurück zum Zitat Ballatori E (2001) Unresolved problems in evaluating the quality of life of cancer patients. Ann Oncol 12:S11–13CrossRefPubMed Ballatori E (2001) Unresolved problems in evaluating the quality of life of cancer patients. Ann Oncol 12:S11–13CrossRefPubMed
3.
Zurück zum Zitat Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 scoring manual (3rd edn). EORTC Quality of Life Group, Brussels, Belgium Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 scoring manual (3rd edn). EORTC Quality of Life Group, Brussels, Belgium
4.
Zurück zum Zitat King MT (1996) The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5:555–567PubMed King MT (1996) The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5:555–567PubMed
5.
Zurück zum Zitat Korea National Statistical Office (2003) Annual Report on the Cause of Death Statistics Korea National Statistical Office (2003) Annual Report on the Cause of Death Statistics
6.
Zurück zum Zitat Modi S, Panageas KS, Duck ET, Bach A, Weinstock N, Dougherty J, Cramer L, Hudis C, Norton L, Seidman A (2002) Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. J Clin Oncol 20:3665–3673CrossRefPubMed Modi S, Panageas KS, Duck ET, Bach A, Weinstock N, Dougherty J, Cramer L, Hudis C, Norton L, Seidman A (2002) Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. J Clin Oncol 20:3665–3673CrossRefPubMed
7.
Zurück zum Zitat Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144PubMed Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144PubMed
8.
Zurück zum Zitat Sharpe M, Strong V, Allen K, Rush R, Postma K, Tulloh A, et al (2004) Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer 90:314–320CrossRefPubMed Sharpe M, Strong V, Allen K, Rush R, Postma K, Tulloh A, et al (2004) Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer 90:314–320CrossRefPubMed
9.
Zurück zum Zitat Skarstein J, Aass N, Fossa SD, Skovlaund E, Dahl AA (2000) Anxiety and depression in cancer patients: relation between the Hospital Anxiety and Depression Scale and the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire. J Psychosom Res 49:27–34CrossRefPubMed Skarstein J, Aass N, Fossa SD, Skovlaund E, Dahl AA (2000) Anxiety and depression in cancer patients: relation between the Hospital Anxiety and Depression Scale and the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire. J Psychosom Res 49:27–34CrossRefPubMed
10.
Zurück zum Zitat Stark D, Kiely M, Smith A, Velikova G, House A, Selby P (2002) Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 20:3137–3148CrossRefPubMed Stark D, Kiely M, Smith A, Velikova G, House A, Selby P (2002) Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 20:3137–3148CrossRefPubMed
11.
Zurück zum Zitat Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, et al (2004) Measuring quality of life in routine oncology practice improves communication and patient wellbeing: a randomized controlled trial. J Clin Oncol 22:714–724CrossRefPubMed Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, et al (2004) Measuring quality of life in routine oncology practice improves communication and patient wellbeing: a randomized controlled trial. J Clin Oncol 22:714–724CrossRefPubMed
12.
Zurück zum Zitat Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al (2004) Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res 13:863–868CrossRefPubMed Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al (2004) Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res 13:863–868CrossRefPubMed
13.
Zurück zum Zitat Zigmund AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361–370PubMed Zigmund AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361–370PubMed
Metadaten
Titel
Changes in quality of life during palliative chemotherapy for solid cancer
verfasst von
Soo-Mee Bang
Se Hoon Park
Hee Geun Kang
Jung In Jue
In Hee Cho
Young Ho Yun
Eun Kyung Cho
Dong Bok Shin
Jae Hoon Lee
Publikationsdatum
01.07.2005
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2005
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-004-0708-0

Weitere Artikel der Ausgabe 7/2005

Supportive Care in Cancer 7/2005 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.